Valuation: Verrica Pharmaceuticals Inc.

Market Cap 59.78M 53.64M 49.59M 44.91M 83.91M 5.69B 84.92M 593M 236M 2.98B 224M 220M 9.46B P/E 2026 *
-1.75x
P/E 2027 * -2.51x
Enterprise Value 59.78M 53.64M 49.59M 44.91M 83.91M 5.69B 84.92M 593M 236M 2.98B 224M 220M 9.46B EV / Sales 2026 *
2.45x
EV / Sales 2027 * 1.52x
Free-Float
50.97%
Yield 2026 *
-
Yield 2027 * -
1 day+0.29%
1 week-4.13%
Current month-27.42%
1 month-24.35%
3 months-35.56%
6 months-46.71%
Current year-58.12%
1 week 3.34
Extreme 3.335
3.76
1 month 3.3
Extreme 3.3
5.04
Current year 3.3
Extreme 3.3
8.95
1 year 3.28
Extreme 3.28
9.82
3 years 3.28
Extreme 3.28
114.1
5 years 3.28
Extreme 3.28
135.35
10 years 3.28
Extreme 3.28
232.9
Manager TitleAgeSince
Chief Executive Officer 50 2024-11-04
Director of Finance/CFO 54 2024-11-04
Chief Tech/Sci/R&D Officer 59 2025-03-25
Director TitleAgeSince
Chairman 70 2017-11-30
Director/Board Member 56 2015-11-30
Director/Board Member 60 2018-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/18/26 Buy

Chief Financial Officer

5,000 0.0291%
8/18/26 Buy

Chief Technology Officer

2,030 0.0118%
8/17/26 Buy

Chief Operating Officer

6,000 0.0349%
Change 5-day change 1-year change 3-year change Capi.($)
+0.29%-4.13%-3.87%-89.67% 59.78M
+0.50%+1.38%+57.09%+129.96% 1,148B
+0.86%+5.14%+45.00%+86.15% 652B
-0.14%+0.42%+25.69%+105.85% 505B
+0.48%+2.12%+53.76%+65.93% 384B
-0.63%-5.97%+61.93%+37.06% 348B
+2.65%+2.62%+34.27%+56.28% 294B
+0.97%-0.77%+2.55%+26.06% 264B
+0.87%+3.08%+54.69%+72.74% 244B
+0.08%+3.67%+35.05%+107.78% 197B
Average +1.11%+0.84%+36.62%+59.81% 403.72B
Weighted average by Cap. +1.16%+1.50%+44.86%+89.07%

Financials

2026 *2027 *
Net sales 24.39M 21.88M 20.23M 18.32M 34.23M 2.32B 34.65M 242M 96.35M 1.22B 91.53M 89.6M 3.86B 39.22M 35.19M 32.53M 29.46M 55.04M 3.74B 55.71M 389M 155M 1.95B 147M 144M 6.2B
Net income -44.37M -39.81M -36.8M -33.33M -62.27M -4.23B -63.02M -440M -175M -2.21B -166M -163M -7.02B -34.56M -31.01M -28.67M -25.97M -48.51M -3.29B -49.1M -343M -137M -1.72B -130M -127M -5.47B
Net Debt - -
Projected Income Statement - Annual - Verrica Pharmaceuticals Inc.
Logo Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Employees
76
Date Price Change Volume
26-10-28 US$3.480 +0.29% 22,369
26-10-27 US$3.470 +1.46% 27,986
26-10-26 US$3.420 -3.12% 21,942
26-10-23 US$3.530 -7.83% 21,005
26-10-22 US$3.830 +5.51% 109,909
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Verrica Pharmaceuticals Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.480USD
Average target price
13.83USD
Spread / Average Target
+297.51%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Verrica Pharmaceuticals Inc.
  1. Stock Market
  2. Stocks
  3. VRCA Stock